We are pleased to announce the Bio-Rad Quality Control Virtual Conference 2020. This online event brings together Clinical Laboratory Professionals from around the world to discover the latest ...

The non-GAAP financial measures shown in the table above and discussed below exclude certain items detailed later in this press release under the heading "Use of Non-GAAP Reporting." A reconciliation ...

Bio-Rad Laboratories, Inc. BIO posted fourth-quarter 2025 adjusted earnings per share (EPS) of $2.51, which missed the Zacks Consensus Estimate by 2.3%. The bottom line decreased 13.4% from the ...

According to MarketsandMarkets, the Food Pathogen Safety Testing Equipment & Supplies Market is projected to reach USD 13.25 billion by 2031 ...

Bio-Rad is providing its financial outlook for the full-year 2026. The Company currently expects non-GAAP, currency neutral revenue growth of approximately 0.5 to 1.5 percent and an estimated non-GAAP ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago. These ...

Bio-Rad’s business segments and geographic revenue distribution for Q4 2025 reveal the company’s diversified market presence: Segment Performance Analysis The Clinical Diagnostics segment emerged as ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...

Bio-Rad Laboratories Inc. reports fourth-quarter results Thursday after market close, with investors looking to see whether the life sciences tools maker can sustain momentum from a strong prior ...

Bio-Rad Laboratories shares fell as the company faces margin pressure related to declining academic research funding. The stock slipped 10.6% to $261.43 Friday. Shares are down 14% over the past 12 ...

Bio-Rad develops products and solutions for the life sciences research and clinical diagnostic markets and enjoys niche market leadership in diagnostic quality controls, antigens, and digital ...